Johan Maervoet is a Consultant in Quintiles' Advisory Services, a role in which he is mainly involved with the development of cost-effectiveness models and supports clients with the preparation of HTA submissions in therapeutic areas including oncology, cardiovascular diseases, musculoskeletal conditions, respiratory diseases, ophthalmology, and infectious diseases.
He started his professional career as a clinical trial pharmacist (qualified person) at a phase I/IIa research unit and, before joining Quintiles, gained 5 years of experience in market access and health economics by working as a consultant in the pharmaceuticals practices of McKinsey & Co. and Deloitte. He is the (co-)author of more than a dozen peer-reviewed papers, multiple ISPOR posters and presentations, and a whitepaper entitled “Identifying efficiencies in the provision of vaccines."
Johan graduated from the University of Antwerp as an industrial pharmacist in 2002, after which he pursued a PhD in toxicology and an MBA at Vlerick Business School. He successfully completed advanced health economic modelling courses (Universities of York and Glasgow) and obtained the European Market Access University Diploma (EMAUD).